Cempra, Inc. to Present at Baird's 2013 Health Care Conference and Stifel Healthcare Conference 2013

Cempra, Inc. to Present at Baird's 2013 Health Care Conference and Stifel
Healthcare Conference 2013

CHAPEL HILL, N.C., Sept. 3, 2013 (GLOBE NEWSWIRE) -- Cempra, Inc.
(Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing
antibiotics to meet critical medical needs in the treatment of bacterial
infectious diseases, today announced that Mark Hahn, executive vice president
and chief financial officer of Cempra, will present at Baird's 2013 Health
Care Conference at 1:45 p.m. EDT, Sept. 11, at The New York Palace Hotel in
New York, and at the Stifel Healthcare Conference 2013 at 8:35 a.m. EDT, Sept.
12, at the Four Seasons Hotel in Boston. Mr. Hahn will discuss the company's
two differentiated antibiotics, solithromycin (CEM-101) for community-acquired
bacterial pneumonia and TAKSTA (CEM-102 or fusidic acid) for the chronic, oral
treatment of Gram-positive pathogens including methicillin-resistant S. aureus
(MRSA) in prosthetic joint infections.

About Cempra, Inc.

Founded in 2006, Cempra, Inc. is a clinical-stage pharmaceutical company
focused on developing antibiotics to meet critical medical needs in the
treatment of bacterial infectious diseases. Cempra's two lead product
candidates are currently in advanced clinical development. Solithromycin
(CEM-101) is in a Phase 3 clinical trial for community-acquired bacterial
pneumonia (CABP) and is licensed to strategic partner Toyama Chemical Co.,
Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain exclusive
rights in Japan. TAKSTA™ (CEM-102) is Cempra's second product candidate, which
is currently in a Phase 2 clinical trial for prosthetic joint infections. Both
seek to address the need for new treatments targeting drug-resistant bacterial
infections in the hospital and in the community. The company also intends to
use its series of proprietary lead compounds from its novel macrolide library
for uses such as the treatment of chronic inflammatory diseases, endocrine
diseases and gastric motility disorders. Additional information about Cempra
can be found at www.cempra.com.

Please Note: This press release contains forward-looking statements regarding
future events. These statements are just predictions and are subject to risks
and uncertainties that could cause the actual events or results to differ
materially. These risks and uncertainties include, among others: the costs,
timing, regulatory review and results of our studies and clinical trials; our
need to obtain additional funding and our ability to obtain future funding on
acceptable terms; our ability to obtain FDA approval of our product
candidates; our dependence on the success of solithromycin and Taksta; our
anticipated capital expenditures and our estimates regarding our capital
requirements; the possible impairment of, or inability to obtain, intellectual
property rights and the costs of obtaining such rights from third parties; the
unpredictability of the size of the markets for, and market acceptance of, any
of our products, including solithromycin and Taksta; our ability to produce
and sell any approved products and the price we are able realize for those
products; our ability to retain and hire necessary employees and to staff our
operations appropriately; our ability to compete in our industry; innovation
by our competitors; and our ability to stay abreast of and comply with new or
modified laws and regulations that currently apply or become applicable to our
business. The reader is referred to the documents that we file from time to
time with the Securities and Exchange Commission.

CONTACT: Investor and Media Contacts:
         Robert E. Flamm, Ph.D.
         Russo Partners, LLC
         (212) 845-4226
         Robert.flamm@russopartnersllc.com
        
         Andreas Marathovouniotis
         Russo Partners, LLC
         (212) 845-4235
         Andreas.marathis@russopartnersllc.com
 
Press spacebar to pause and continue. Press esc to stop.